138.86
+5.41%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Kymera Therapeutics
From its filings with the US Securities and Exchange Commission
Kymera Therapeutics is based in Watertown, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker KYMR. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $39.2m and a net loss of $311.4m. At that date it held total assets of $1.74bn and shareholders' equity of $1.58bn.
We are a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of innovative, highly differentiated oral medicines that address significant health problems and meaningfully improve patients’ lives. We are committed to advancing novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Our approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner.
We are a leader in targeted protein degradation (TPD), a next-generation small molecule therapeutic modality that engages the body’s natural cellular recycling system to selectively eliminate disease-causing proteins. Our objective is to develop molecules that are both potent and highly selective, creating the unique potential to address diseases that are poorly served by current treatment options. To date, we have progressed multiple programs into clinical development and expect to advance at least one new molecular entity into clinical testing annually. We intend to leverage our drug development expertise to become a fully integrated biopharmaceutical company with an industry-leading pipeline of novel medicines.
Quoted from its 10-K, filed 26 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 21 Aug 2020
- Employees
- 238
- Website
- kymeratx.com ↗
- Head office
- 500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN, MA, 02472
- Incorporated in
- DE
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Dr. Bruce BoothIndependent Chairman of the Board, Co-Founder, since 2015$372,722
- Dr. Nello MainolfiPresident, Chief Executive Officer, Co-Founder, Director, since 2019$15.4m
- Mr. Bruce JacobsChief Financial Officer$7.1m
- Dr. Jeremy ChadwickChief Operating Officer$3.5m
- Dr. Jared GollobChief Medical Officer$5.7m
- Mr. Noah GoodmanChief Business Officer
- Mr. Brian AdamsChief Legal Officer, Corporate Secretary
- Dr. Felix BakerLead Independent Director$842,171
- Mr. Jeffrey AlbersIndependent Director$361,805
- Dr. Pamela EspositoIndependent Director$357,097
- Dr. Gorjan HrustanovicIndependent Director$347,722
- Dr. John MaraganoreIndependent Director$349,597
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 48
- Environment
- 53
- Social
- 46
- Governance
- 46
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Kymera Therapeutics' Pegasus platform enables targeted protein degradation for immune-inflammatory diseases.
- The company's clinical-stage programs IRAK4 and STAT3 address key targets in IL-1R/TLR and JAK/STAT pathways.
- Kymera employs 238 full-time employees focused on biopharmaceutical innovation in Watertown, Massachusetts.
Weaknesses
- Kymera's IPO in 2020 marks a relatively short operational history for a biopharmaceutical company.
- The company's focus on small molecule therapeutics may limit its ability to address complex protein targets.
- Kymera's clinical-stage programs require significant investment for further development and approval.
Opportunities
- Expanding the Pegasus platform to target additional disease-causing proteins in immune-inflammatory conditions.
- Growing demand for targeted protein degradation therapies in the Health Care sector.
- Potential partnerships with larger pharmaceutical companies to accelerate clinical development.
Threats
- Competition from other biopharmaceutical companies developing similar protein degradation technologies.
- Regulatory challenges in approving novel small molecule therapeutics for immune-inflammatory diseases.
- Market volatility affecting biotech IPOs and funding for early-stage companies like Kymera.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.